Mesothelioma Lump Sum Payments (Conditions and Amounts) (Amendment) Regulations 2023

Viscount Younger of Leckie Excerpts

Monday 6th March 2023 Grand Committee

Moved by

[Viscount Younger of Leckie]

That the Grand Committee do consider the Mesothelioma Lump Sum Payments (Conditions and Amounts) (Amendment) Regulations 2023.

[The Parliamentary Under-Secretary of State, Department for Work and Pensions (Viscount Younger of Leckie) (Con)]

My Lords, I will speak also to the Pneumoconiosis etc. (Workers’ Compensation) (Payment of Claims) (Amendment) Regulations 2023. I am pleased to introduce these statutory instruments, which were laid before the House on 12 January 2023. These instruments will increase the value of lump sum awards payable under the Pneumoconiosis etc. (Workers’ Compensation) Act 1979, and the diffuse mesothelioma scheme, which was established by the Child Maintenance and Other Payments Act 2008.

As many noble Lords will be aware, these two schemes are not included in the main social security benefits uprating procedure and their uprating is not a statutory requirement. However, through these statutory instruments, we will increase the amounts payable by the September 2022 consumer prices index of 10.1%. These new amounts will be paid to those who satisfy all the conditions of entitlement for the first time on or after 1 April 2023.

Many noble Lords will be aware of friends and close colleagues from your Lordships’ House who have lost their lives as a result of these dreadful diseases. We must remember the great impact that these diseases have on people and their families. The Government recognise the tremendous suffering that diseases such as mesothelioma and pneumoconiosis cause to those who are diagnosed. The conditions covered by these schemes can be debilitating and life limiting and often involve very long latency periods, with symptoms starting to show many years, often many decades, after exposure. Mesothelioma, for example, is an aggressive type of cancer strongly associated with exposure to asbestos and is usually terminal. Life expectancy from diagnosis is poor.

I will now outline the purpose of the two schemes we are debating. The Pneumoconiosis etc. (Workers’ Compensation) Act 1979, which, for simplicity, I shall refer to as the 1979 scheme, provides a single lump sum compensation payment to individuals who suffer from one of the prescribed diseases covered by the scheme, including mesothelioma, pneumoconiosis and three other dust-related respiratory diseases. This scheme was designed to cover people who are unable to claim damages from employers because they have gone out of business and who have not brought any action against another party for damages. To be eligible, a claimant must be in receipt of industrial injuries disablement benefit for a disease covered by the 1979 scheme.

The 2008 mesothelioma lump sum payments scheme, which I will refer to as the 2008 scheme, was introduced to provide compensation to people who contracted diffuse mesothelioma but who are unable to claim compensation under the 1979 Act. This may be because they were self-employed or their exposure to asbestos was not due to their work. The 2008 scheme allows payments to be made quickly to people with diffuse mesothelioma at their time of greatest need. Under both schemes, a claim can be made by a dependant if the person with the disease has sadly died before being able to make a claim. These schemes aim to ensure that, where possible, the people who suffer from the diseases they cover receive compensation within their lifetime.

The rates payable under the 1979 Act scheme are based on the disease sufferer’s assessed level of disablement and their age at the date of entitlement. The highest awards are made to individuals with the highest assessed level of disablement and those who become entitled to a payment at an earlier age.

All payments for diffuse mesothelioma under the 1979 Act scheme are automatically made at the 100% disablement rate—the highest rate of payment—reflecting the serious nature of the disease. Similarly, all payments for this condition under the 2008 scheme are made at the 100% disablement rate. The highest payments from both schemes are made to the youngest sufferers of the disease. Between April 2021 and March 2022, the latest financial year for which data is available, 3,080 awards were made across both schemes, totalling £44.7 million. Between 2022-23 and 2027-28, expenditure on these schemes is forecast to fall by 8% in real terms.

I will now touch on the legacy of Covid-19. As the Committee will be aware, the Covid-19 pandemic presented unprecedented challenges. I am mindful of the impact it has had on sufferers of respiratory diseases in particular. As my predecessor set out in last year’s debate, the department made the decision to suspend all face-to-face assessments between March 2020 and April 2021 to protect the health of our claimants, and of course our staff. Some assessments were further suspended beyond April 2021 due to the additional risks of undertaking them face to face. Inevitably, this has led to delays in some customer journeys for claims to industrial injuries disablement benefit and the lump-sum schemes.

In response, the department and its assessment provider, the Centre for Health and Disability Assessments, introduced several innovations to ensure that claims for IIDB, the 1979 scheme and the 2008 scheme continued to be processed as quickly as possible. We increased the use of paper-based assessments and introduced video assessments where appropriate. I am pleased to say that we continue to assess some customers via these routes where possible.

I will now touch on one specific, important and sensitive theme linked to these regulations, which is asbestos removal and schools. Tremendous strides have been made to restrict the use of asbestos and introduce safe environments for its handling in this country. However, the legacy of its widespread use, including in schools, is still with us today.

The Health and Safety Executive has a mature and comprehensive regulatory framework to ensure that the legacy asbestos risks in Great Britain are managed, which aligns with the best evidence currently available. Correct implementation of the Control of Asbestos Regulations 2012 not only ensures management of the risks of exposure but will eventually lead to the elimination of asbestos from the built environment. I understand that some noble Lords have previously raised the issue of asbestos in schools in these debates. I assure them, and this Committee, that the Government take the safety of children and those who work with them incredibly seriously.

The Department for Education is committed to working collaboratively with the regulator, the HSE, to support schools and duty holders. As part of this, the Department for Education published bespoke guidance on asbestos management for schools in 2020 and is working with the HSE and the sector to look at further ways to help them and to build on existing guidance and support. Well-maintained and safe school buildings are a priority for this Government. That is why over £13 billion has been allocated for improving school buildings since 2015, including £1.8 billion committed for the financial year 2022-23.

I will conclude on a positive and—I hope noble Lords will agree—hopeful note. While there is always a degree of uncertainty in predicting future disease incidence, current projections by the Health and Safety Executive suggest that total annual mesothelioma deaths in Great Britain are expected to decline in the coming decades. For males, a decline is projected over the course of this decade, and for females, deaths are projected to start falling shortly after. These figures offer some hope that, one day, no more families shall have to endure the suffering caused by these dreadful diseases.

Medical research into treatment options is ongoing, particularly in the field of immunotherapy. While these treatments are not currently curative, a recent trial has shown clear evidence of benefit to advanced mesothelioma patients, equivalent to an additional three to four months of life.

I am sure that all noble Lords here today will join me in recognising the continued importance of the compensation provided by the 1979 and 2008 schemes and the importance of maintaining the value of these payments at this time. I am pleased to say that these regulations were considered in the other place on 8 February 2023.

Finally, as part of my role today, I am required to confirm—which I am pleased to do—that these provisions are compatible with the European Convention on Human Rights. I commend to the Committee the increase of the payment scales for these schemes and ask approval to implement them. I beg to move.

[Lord Alton of Liverpool (CB)]

My Lords, I thank the noble Viscount for the way in which he introduced these regulations. Just before we began, a group of us were recalling how we have discussed this year in, year out. We were also recalling some of his illustrious predecessors and others in all parts of the House who contributed to some of the changes that he has referred to.

I am thinking particularly of the late Lord Newton of Braintree, who was a Secretary of State. He was a great supporter when I moved amendments in your Lordships’ House seeking to change the Criminal Justice Bill and to bring about what then became a full-scale Act of Parliament, the Mesothelioma Act. The noble Lord, Lord Freud, was decisive in making that happen. He also once shared in this Committee how his father had died of mesothelioma. On this side of the Committee, I think of Lord McKenzie of Luton, who died at the end of 2021. It will seem a strange debate without his voice. His attention to granular detail was extraordinary and his knowledge of pneumoconiosis and mesothelioma admirable, demonstrating the very best of your Lordships’ House.

The noble Viscount referred to the removal of asbestos from schools, which I was very pleased to hear about. It has been a recurring theme that we have raised in these Committees over the years. On a hopeful note, he said that mesothelioma might be plateauing. I will come back to the data a bit later. He also talked about advances in medical treatments. He will know that the Mesothelioma Act was specifically about providing government funding toward the work of the British Lung Foundation and others on the causes and consequences of mesothelioma and on looking for cures. Can the noble Viscount tell us more about whether that funding is being sustained and what progress is being made in that area?

One of the things that has struck me is the number of noble Lords who have shared personal stories of loved ones, family or friends who have died of this disease, which, over the distance, has claimed more than 30,000 lives. That is the same number of deaths still estimated to be caused globally every year. As I have done on previous occasions, I pay tribute to John Flanagan and the Liverpool-based charity, the Merseyside Asbestos Victims Support Group, for keeping a candle lit for all those afflicted by mesothelioma. In 2020, I noted that people in Liverpool are more than 18% more likely to die of mesothelioma. I know that we will hear from my noble friend Lord Wigley and the noble Lord, Lord Jones, during our proceedings; we have heard from them previously about the situation in Wales. However, this disease is no respecter of geographical boundaries or class. Indeed, the noble Lord, Lord Allan of Hallam, and I were discussing this just before the Committee met. We were talking about some of those who have talked about the loss of loved ones.

My noble friend Lord Freyberg talked in the House about his sister, a journalist, who had died of mesothelioma. The noble Lord, Lord McNally, talked about his sister, who had simply been washing overalls and had died of mesothelioma. The noble Lord, Lord Giddens, told us about his wife, who had died of mesothelioma. We also heard from the noble Lord, Admiral Lord West, the story of how young men training for the Navy played snowballs with asbestos. Indeed, Jeremy Hunt, the Chancellor of the Exchequer, described how his father, Admiral Hunt, had also died of mesothelioma. So this is not something that is remote. It is something we know about, but sometimes it is regarded almost as having Cinderella status.

--- Later in debate ---

I was very pleased to hear the good news from the Minister about work being done in schools and about progress in using the benefits of the pandemic time—finding novel ways to take evidence remotely from applicants, for example, which is very welcome. I will be interested also to hear what is happening with research and welcome again the improvements on the medical front, such as immunotherapy, which at least help to prolong by some small amount the lives of those suffering from mesothelioma. We are, as always, very happy to support the uprating of these lump sum payments in line with inflation. I look forward to the Minister’s reply.

[Viscount Younger of Leckie (Con)]

I thank the Committee and all noble Lords for participating this afternoon, and for their general support for these regulations. I noticed that the noble Lord, Lord Jones, described our approach as humane; I might think that was a little bit of an understatement, but I appreciate the comments that he made.

I will pick up on some of the comments made by the noble Lord, Lord Alton. He did the Committee a huge service by reminding us about the historical context of this. We should remember, as he rightly said, Lord Newton of Braintree, who I remember—just, as a much younger person—as Tony Newton. I think he was an ex-Health Secretary. It was helpful to hear the noble Lord’s comments there and to remind ourselves, as we do need reminding, of my noble friend Lord Freud, who did so much in this area. We should particularly remember Lord McKenzie of Luton—the noble Baroness, Lady Sherlock, is completely right on that—who was so active in this House and did so much for it.

On a personal note, I also want to mention a very dear friend who died of mesothelioma about 18 months ago. He was a quite remarkable individual who survived for eight years. He told me that he knew the longest surviving period of time was seven years and he managed, through thick and thin, to survive for eight. He was an incredible individual who gained an MBE for the work that he did in prisons, so I always remember that.

A number of questions were asked and I will start by saying that the Government recognise that the two schemes we are debating are a crucial part of the support available to people suffering from these dust-related diseases. It is right that we maintain the value of these payments at this time. In addition to the compensation awarded through these schemes, the department provides specific support for those who have industrial injuries, or diseases caused by occupational exposure, through industrial injuries disablement benefit, a weekly payment based on the assessed level of disablement. Other state benefits may also be available to claimants of the schemes to cover other needs, such as income replacement and caring costs, as well as further costs arising from their disability.

I want to pick up an important point raised by the noble Lord, Lord Alton of Liverpool, which was followed up by the noble Lord, Lord Allan of Hallam, on the question of funding. Research is crucial in the fight against cancer and the Department of Health and Social Care invested £98.3 million in cancer research in 2021-22, through the National Institute for Health and Care Research. For several years, we have been working actively to stimulate an increase in the level of mesothelioma research activity from a pretty low base. This includes a formal research priority setting exercise, a National Cancer Research Institute workshop and a specific call for research proposals through the National Institute for Health and Care Research—so those are important points to be made.

The noble Lord, Lord Alton, asked about schemes comparable with civil damages claims. When the DMPS was introduced in 2014, the payment tariffs were based on 80% of the average damages award in the civil courts. As a result of the Diffuse Mesothelioma Payment Scheme (Amendment) Regulations that were laid on 27 February 2015 and came into effect on 31 March 2015, the tariffs increased from 80% of average civil claims to 100%. Since then, the tariff payments have remained the same. However, in line with commitments made during the passage of the Mesothelioma Bill, working collaboratively with the insurance industry and other key stakeholder groups, the department has now started to progress the tariff review to ensure that the expectations of the stakeholder lobby groups are managed and that, fundamentally, the payments are still commensurate with damages awarded in civil cases for occupational mesothelioma.

The noble Lord also raised equalisation. I hope that I can give him a reasonably comprehensive answer on this, because there is often much interest in the Government’s position on equalisation of payments made to dependents with those made to the sufferers of these diseases. I have listened carefully to the concerns raised today by the noble Lord. The Government remain of the view that available funding should be prioritised for those currently living with the disease to support them in dealing with the challenges that these illnesses bring in life. It is therefore right that available funding should be targeted where it is needed most. Indeed, around 90% of payments made under both schemes are paid to the sufferers of the diseases covered by them. However, it is of course clear that whole families can be devastated by the diseases covered by the lump sum schemes, which is why dependants are still entitled to some compensation under the schemes.

The noble Lords, Lord Jones and Lord Wigley, asked a number of specific questions on the figures involved. I will do my best to answer them, although I fear that there may be a letter arriving after my comments. As a generic response to the noble Lord, Lord Wigley, on the numbers per sector, data on mesothelioma deaths in Great Britain is published on the Health and Safety Executive website, on the health and safety statistics page under the sub-heading “Ill health”. These statistics include analyses of the relative frequency of recording of different occupations on mesothelioma death certificates, which are more useful as an indication of potential past sources of occupational asbestos exposure than absolute numbers recorded for particular occupations.

The noble Lords, Lord Wigley, Lord Jones and Lord Allan, asked about the breakdown of costs by region. The noble Lord, Lord Jones, also asked about quarrymen and those working in the slate industry. I feel that I will need to write to him on that. Volumes of awards through the 1979 and 2008 schemes, broken down by region, are now published. Unfortunately, information on the occupational breakdown of these awards is not published or readily available. This would require analysis of multiple datasets for the 1979 scheme and the industrial injuries disablement benefit scheme to determine industry information. Information on IIDB assessments is published on Stat-Xplore. I will write to see what more I can do to help all noble Lords on this point.

However, I might be able to help in one respect. The noble Lord, Lord Allan, asked, perhaps more as an aside, whether I could give some figures on the sex of those who have suffered. It is fairly simple: in 2017-18, the breakdown was 5% female and 95% male; the overall figures from then until 2021-22 are 7% female and 93% male. I hope that is of some help.

The noble Lord, Lord Allan, and the noble Baroness, Lady Sherlock, asked why statutory uprating should not be done on a regular basis—and this may be asked every year. Perhaps I can make some reassurances to this Committee that, although there is no statutory requirement to review the level of these payments annually, DWP Ministers have agreed to uprate payments under both the 1979 and the 2008 scheme together in line with inflation each year since 2010. A change of this nature is unlikely to make any monetary difference to those who receive awards under these schemes. Making this a statutory requirement would require amendments to primary legislation and, even with amended primary legislation, it is probable that statutory instruments would still be required to uprate the schemes annually. As such, parliamentary debates on this subject would continue. I add that these debates provide a valuable avenue to raise awareness of the lump sum schemes and, more broadly, support for people with respiratory diseases. That point was raised by the noble Baroness, Lady Sherlock, and I very much appreciated that.